Certara's Participation in Major Investment Conference
Certara, Inc. (Nasdaq: CERT), a leading name in model-informed drug development, has announced its upcoming participation in a prominent investment conference. The team at Certara is ready to share their insights and innovations that are propelling the future of medicine.
Details of the Conference Presentation
The management of Certara will present on Thursday morning. Industry stakeholders and interested parties alike are invited to tune in to the live session, which promises to deliver valuable information regarding Certara's strategic direction and new developments in the field of biopharmaceutical modeling.
What to Expect from the Presentation
Attendees can look forward to an overview of Certara's cutting-edge biosimulation software and technology. The team will discuss how these innovations are reshaping traditional drug discovery and development practices. With a global client base, including over 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies, Certara is at the forefront of revolutionizing how new therapies are brought to market.
Accessing the Live Webcast
Investors and interested parties can access the live presentation through Certara's investor relations website. The webcast will be available not only live but will also be recorded for later viewing, allowing those who cannot attend the event live to gain insights at their convenience.
About Certara
Certara stands out in the biopharmaceutical landscape by enabling faster development of drugs through advanced biosimulation technologies. Their commitment to efficiency and innovation helps accelerate the journey from concept to market for critical new medications.
Contact Information for Investors and Media
For those looking to engage with Certara further, the company has provided dedicated contact points for investor relations and media inquiries. This open line of communication reflects Certara's commitment to transparency and engagement with its stakeholders.
Investor Relations Contact
David Deuchler from the Gilmartin Group is the primary contact for investor relations, ensuring that all inquiries are handled efficiently and professionally.
Media Contact
Alyssa Horowitz represents the media inquiries, offering another layer of accessibility for those wishing to learn more about Certara's initiatives and impact in the biopharmaceutical sector.
Frequently Asked Questions
What is the main focus of Certara's presentation at the conference?
Certara will present its advancements in biosimulation technology and how it influences drug development processes.
How can I access the webcast of the presentation?
The webcast will be available on Certara’s investor relations website and will also be recorded for future access.
What makes Certara a leader in the biopharmaceutical industry?
With over 2,400 clients across 66 countries, Certara utilizes innovative software to optimize the drug development process.
Who can I contact for more information about Certara?
Investor inquiries can be directed to David Deuchler, while media inquiries should be sent to Alyssa Horowitz.
When is the presentation scheduled?
The management's presentation at the Stephens Annual Investment Conference is set for Thursday morning.
